overweight / obesity 40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor q5y q1y q1-2y mammogram based on life expectancy / health status q15y 3% Timed up and go test 1 dose; 2 doses (2-6 months apart) if immunocomp hormone therapy aromatase inhibitors ovarian cancer pneumococcal 40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors ≥ 6.5% ≥ 20% 40-70 y.o., ASCVD ≥ 10%, low bleeding risk 75 y.o. colorectal cancer 50 y.o. 40-59 y.o., ASCVD ≥ 10%, low bleeding risk dyslipidemia ≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors Gail model ≥ 126 mg/dL 40 y.o. ≥ 200 mg/dL breast cancer 65 y.o. cardiovascular disease tobacco use ≤ q2y q1y mammogram anxiety 60 y.o. q2y Fracture Risk Assessment Tool dementia ≥ 5.7% raloxifene tamoxifen Tyrer- Cuzick model lung cancer 40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor aspirin HIV diabetes community- dwelling, postmenopausal women 2 doses, 2-6 months apart depression ≥ 100 mg/dL insufficient evidence for screening < 60 y.o. ≥ 140 mg/dL herpes zoster Hepatitis C 52 y.o. women age 55- 64 y.o. multidose initial series, then 1 dose at 2-6 months PREVENT equation cervical cancer q3y statin hypertension Hepatitis B overweight / obesity 40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor q5y q1y q1-2y mammogram based on life expectancy / health status q15y 3% Timed up and go test 1 dose; 2 doses (2-6 months apart) if immunocomp hormone therapy aromatase inhibitors ovarian cancer pneumococcal 40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors ≥ 6.5% ≥ 20% 40-70 y.o., ASCVD ≥ 10%, low bleeding risk 75 y.o. colorectal cancer 50 y.o. 40-59 y.o., ASCVD ≥ 10%, low bleeding risk dyslipidemia ≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors Gail model ≥ 126 mg/dL 40 y.o. ≥ 200 mg/dL breast cancer 65 y.o. cardiovascular disease tobacco use ≤ q2y q1y mammogram anxiety 60 y.o. q2y Fracture Risk Assessment Tool dementia ≥ 5.7% raloxifene tamoxifen Tyrer- Cuzick model lung cancer 40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor aspirin HIV diabetes community- dwelling, postmenopausal women 2 doses, 2-6 months apart depression ≥ 100 mg/dL insufficient evidence for screening < 60 y.o. ≥ 140 mg/dL herpes zoster Hepatitis C 52 y.o. women age 55- 64 y.o. multidose initial series, then 1 dose at 2-6 months PREVENT equation cervical cancer q3y statin hypertension Hepatitis B
(Print)
overweight / obesity
40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor
q5y
q1y
q1-2y mammogram based on life expectancy / health status
q15y
3%
Timed up and go test
1 dose; 2 doses (2-6 months apart) if immunocomp
hormone therapy
aromatase inhibitors
ovarian cancer
pneumococcal
40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
≥ 6.5%
≥ 20%
40-70 y.o., ASCVD ≥ 10%, low bleeding risk
75 y.o.
colorectal cancer
50 y.o.
40-59 y.o., ASCVD ≥ 10%, low bleeding risk
dyslipidemia
≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
Gail model
≥ 126 mg/dL
40 y.o.
≥ 200 mg/dL
breast cancer
65 y.o.
cardiovascular disease
tobacco use
≤ q2y
q1y mammogram
anxiety
60 y.o.
q2y
Fracture Risk Assessment Tool
dementia
≥ 5.7%
raloxifene
tamoxifen
Tyrer-Cuzick model
lung cancer
40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor
aspirin
HIV
diabetes
community-dwelling, postmenopausal women
2 doses, 2-6 months apart
depression
≥ 100 mg/dL
insufficient evidence for screening
< 60 y.o.
≥ 140 mg/dL
herpes zoster
Hepatitis C
52 y.o.
women age 55-64 y.o.
multidose initial series, then 1 dose at 2-6 months
PREVENT equation
cervical cancer
q3y
statin
hypertension
Hepatitis B
